Lv1
38 积分 2024-01-17 加入
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
2个月前
已完结
Oesophageal cancer
3个月前
已完结
Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma
8个月前
已完结
Nivolumab Plus Relatlimab: First Approval
8个月前
已完结
Cancer immunotherapy: T cells and neutrophils working together to attack cancers
8个月前
已完结
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
8个月前
已完结
Immune checkpoint therapy—current perspectives and future directions
8个月前
已完结
IGSF8 is an innate immune checkpoint and cancer immunotherapy target
8个月前
已完结
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
8个月前
已完结
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis
1年前
已完结
皖公网安备34019202002308
